Crinela Todea
Adult Health · Alexandria, VANPI 1568685097
Payments from drug & device makers
Across 128 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$464
- Johnson & Johnson$296
- AstraZeneca$250
- Lilly USA, LLC$244
- Amarin Pharma, Inc.$195
- Novo Nordisk$190
- plus $793 from 17 others
What the payments were for
- Food & beverage$2,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 26 | $464 |
| Johnson & Johnson | 4 | $296 |
| AstraZeneca | 16 | $250 |
| Lilly USA, LLC | 15 | $244 |
| Amarin Pharma, Inc. | 12 | $195 |
| Novo Nordisk | 11 | $190 |
| AbbVie | 7 | $115 |
| GSK | 4 | $109 |
| Otsuka America Pharmaceutical, Inc. | 7 | $98 |
| Pfizer | 5 | $76 |
| Organon | 2 | $58 |
| Eisai Inc. | 3 | $47 |
| Novartis | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $40 |
| Coopersurgical, Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Dexcom, Inc. | 2 | $26 |
| Bayer | 2 | $24 |
| Ascend Therapeutics US, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Abbott | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125
How this compares
$2,432 in reported general payments places this provider in the 75th percentile of 368 adult health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $13,754 |
| LinzessLinaclotide | 12 | $6,378 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $951 |
| Omeprazole | 22 | $567 |
| Fluticasone Propionate | 34 | $434 |
| Atorvastatin Calcium | 51 | $388 |
| Pantoprazole Sodium | 20 | $358 |
| Rosuvastatin Calcium | 16 | $323 |
| Montelukast Sodium | 41 | $279 |
| Amlodipine Besylate | 54 | $257 |
| Metoprolol Succinate | 17 | $252 |
| Losartan Potassium | 24 | $212 |
| Metformin Hcl | 35 | $211 |
| Levothyroxine Sodium | 21 | $207 |
| Glipizide | 17 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $13,75415 claims |
| AbbVieLinzess | $115 | $6,37812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 368 adult health providers in Virginia.
Other adult health in Alexandria
- Julia CamargoAlexandria$8K
- Robin KorinAlexandria$6K
- Amanda LawtonAlexandria$5K
- Valerie ChrosniakAlexandria$5K
- Ashley LoweAlexandria$4K
- Kerry McGonagleAlexandria$4K
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
- Chelsea KoskovichFredericksburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.